ADMA Biologics Inc vs Teladoc Health Inc — how do they compare? ADMA Biologics Inc trades at $9.9 (market cap $2.22B), while Teladoc Health Inc trades at $6.64 (market cap $1.24B). The key difference: ADMA Biologics Inc is the larger of the two by market cap, and Teladoc Health Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | TDOC | |
|---|---|---|
Market Cap | $2.22B | $1.24B |
Sector | Health | Health |
52-Week High | $20.38 | $9.72 |
52-Week Low | $7.60 | $4.47 |
Enterprise Value | $2.29B | $1.50B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Teladoc Health (TDOC) trades at $7.08, down 0.7% for the day, with a bearish technical signal and negative earnings. The stock faces pressure from a recent 28% drop after Q2 2026 revenue missed estimates and full-year guidance was cut. Valuation metrics like P/S of 0.49 and EV/EBITDA of 6.96 appear low, but profitability remains weak with a -7.13% net income margin. Multiple law firms are investigating potential securities violations, adding to investor concerns.
The outlook is cautious due to ongoing losses and competitive pressures in virtual care. Risks include execution challenges at the BetterHelp unit and regulatory scrutiny. Analyst consensus is mixed with a $8.88 price target, but near-term volatility is likely amid negative sentiment and fundamental headwinds.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →